Literature DB >> 16356996

Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: what does evidence from randomised trials show about celecoxib?

Jonathan L Underhill.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16356996      PMCID： PMC1315706          DOI： 10.1136/bmj.331.7530.1474-c

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

Authors:  Peter Jüni; Anne W S Rutjes; Paul A Dieppe
Journal:  BMJ       Date:  2002-06-01

Review 2.  How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?

Authors:  Nick Freemantle
Journal:  BMJ       Date:  2005-10-08

3.  Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.

Authors:  Julia Hippisley-Cox; Carol Coupland; Richard Logan
Journal:  BMJ       Date:  2005-12-03

4.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.